{"nctId":"NCT01500226","briefTitle":"Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy","startDateStruct":{"date":"2012-02"},"conditions":["Chemotherapy-induced Nausea and Vomiting"],"count":1369,"armGroups":[{"label":"Placebo + Granisetron + Dexamethasone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Granisetron","Drug: Dexamethasone","Drug: Placebo"]},{"label":"Rolapitant","type":"EXPERIMENTAL","interventionNames":["Drug: Rolapitant","Drug: Granisetron","Drug: Dexamethasone"]}],"interventions":[{"name":"Rolapitant","otherNames":["Varubi"]},{"name":"Granisetron","otherNames":["Kytril","Granisol"]},{"name":"Dexamethasone","otherNames":["Decadron"]},{"name":"Placebo","otherNames":["Placebo to match Rolapitant"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years of age or older, of either gender, and of any race\n* Naïve to moderately or highly emetogenic chemotherapy, and is to receive a first course of MEC including one or more of the following agents: cyclophosphamide IV (\\<1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, cytarabine IV (\\>1 g/m2).\n* Karnofsky performance score of ≥60\n* Predicted life expectancy of ≥4 months\n* Adequate bone marrow, kidney, and liver function\n\nExclusion Criteria:\n\n* Contraindication to the administration of prescribed MEC agent,granisetron, or dexamethasone\n* Is pregnant or breast feeding\n* Has taken the following agents within the last 48 hours 5-HT3 antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist, Benzodiazepines\n* Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3 or above (Hesketh Scale) from Day -2 through Day 6, except on Day 1\n* Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5 through Day 6\n* Has received systemic corticosteroids or sedative antihistamines within 72 hours of Day 1 of the study except as premedication for chemotherapy (e.g., taxanes)\n* Symptomatic primary or metastatic CNS disease.\n* Has ongoing vomiting, retching, clinically significant nausea caused by any etiology, or has a history of anticipatory nausea and vomiting.\n* Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of MECon Day 1 in Cycle 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"No Emetic Episodes and No Rescue Medication","description":"The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (\\>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (\\>24 to 120 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"61.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Phase Response","description":"To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null},{"groupId":"OG001","value":"80.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"57.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":89,"n":670},"commonTop":["Fatigue","Alopecia","Constipation","Diarrhoea","Headache"]}}}